Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1/Signature 2

From BugSigDB
Reviewed Marked as Reviewed by Folakunmi on 2024-2-13

Curated date: 2021/01/10

Curator: William Lam

Revision editor(s): Atrayees, WikiWorks, Folakunmi

Source: Figure 2b

Description: Comparsion of partial response/ stable disease and progressive disease in fecal samples of all patients with non-small cell lung cell lung carcinoma (NSCLC) or renal cell carcinoma (RCC) reponse at 3 months of PD-1 monoclonal antibodies (mAB) treatment

Abundance in Group 1: decreased abundance in Responders (partial response or stable disease)

NCBI Quality ControlLinks
Bacillota bacterium
Bacteroides clarus
Bacteroides nordii
Blautia
Clostridiales bacterium
Clostridium sp.
Enterocloster bolteae
Parabacteroides distasonis
Prevotella
Pseudomonadota
unclassified Eubacteriales

Revision editor(s): Atrayees, WikiWorks, Folakunmi